These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25297015)

  • 1. CGRP as a new target in prevention and treatment of migraine.
    Diener HC
    Lancet Neurol; 2014 Nov; 13(11):1065-1067. PubMed ID: 25297015
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.
    Dodick DW; Goadsby PJ; Silberstein SD; Lipton RB; Olesen J; Ashina M; Wilks K; Kudrow D; Kroll R; Kohrman B; Bargar R; Hirman J; Smith J;
    Lancet Neurol; 2014 Nov; 13(11):1100-1107. PubMed ID: 25297013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention.
    Med Lett Drugs Ther; 2018 Nov; 60(1559):177-180. PubMed ID: 30681655
    [No Abstract]   [Full Text] [Related]  

  • 4. Calcitonin Gene-Related Protein (CGRP)-Targeted Treatments for Migraine Prevention.
    Tepper DE
    Headache; 2019 Mar; 59(3):477-480. PubMed ID: 30825209
    [No Abstract]   [Full Text] [Related]  

  • 5. Wiping Out CGRP: Potential Cardiovascular Risks.
    MaassenVanDenBrink A; Meijer J; Villalón CM; Ferrari MD
    Trends Pharmacol Sci; 2016 Sep; 37(9):779-788. PubMed ID: 27338837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Nichols R; Skljarevski V; Dell'Agnello G; Hundemer HP; Aurora SK
    J Headache Pain; 2019 Mar; 20(1):22. PubMed ID: 30823868
    [No Abstract]   [Full Text] [Related]  

  • 7. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CGRP antibodies: a new approach to migraine prevention.
    Reuter U
    Lancet Neurol; 2014 Sep; 13(9):857-9. PubMed ID: 25127171
    [No Abstract]   [Full Text] [Related]  

  • 9. Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.
    Szperka CL; VanderPluym J; Orr SL; Oakley CB; Qubty W; Patniyot I; Lagman-Bartolome AM; Morris C; Gautreaux J; Victorio MC; Hagler S; Narula S; Candee MS; Cleves-Bayon C; Rao R; Fryer RH; Bicknese AR; Yonker M; Hershey AD; Powers SW; Goadsby PJ; Gelfand AA
    Headache; 2018 Nov; 58(10):1658-1669. PubMed ID: 30324723
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic antibodies against CGRP or its receptor.
    Bigal ME; Walter S; Rapoport AM
    Br J Clin Pharmacol; 2015 Jun; 79(6):886-95. PubMed ID: 25614243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.
    Hong P; Wu X; Liu Y
    Clin Neurol Neurosurg; 2017 Mar; 154():74-78. PubMed ID: 28129635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine.
    Parikh SK; Burkett JG; Silberstein SD
    Expert Opin Drug Saf; 2020 May; 19(5):537-543. PubMed ID: 32116061
    [No Abstract]   [Full Text] [Related]  

  • 13. Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.
    Pellesi L; Guerzoni S; Pini LA
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):534-547. PubMed ID: 28409893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.
    Israel H; Neeb L; Reuter U
    Curr Pain Headache Rep; 2018 Apr; 22(5):38. PubMed ID: 29623520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CGRP-targeted antibodies in difficult-to-treat migraine.
    de Vries T; MaassenVanDenBrink A
    Nat Rev Neurol; 2019 Dec; 15(12):688-689. PubMed ID: 31595083
    [No Abstract]   [Full Text] [Related]  

  • 16. TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine.
    Walter S; Bigal ME
    Curr Pain Headache Rep; 2015 Mar; 19(3):6. PubMed ID: 25754596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three new drugs for the prevention of migraine.
    Drug Ther Bull; 2020 Oct; 58(10):151-156. PubMed ID: 32994317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive Treatment for Episodic Migraine.
    Parikh SK; Silberstein SD
    Neurol Clin; 2019 Nov; 37(4):753-770. PubMed ID: 31563231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin Gene-Related Peptide Targeted Therapy for Migraine.
    Tepper DE
    Headache; 2016 Feb; 56(2):447-8. PubMed ID: 26898484
    [No Abstract]   [Full Text] [Related]  

  • 20. A Proposal for Acronyms for Anti-Calcitonin Gene-Related Peptide Antibodies.
    Evans RW; Loftus BD
    Headache; 2018 Apr; 58(4):596. PubMed ID: 29611192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.